Antipsychotic Adverse Events · Chapter 15 · The Clozapine Set
Constipation & Ileus
The Clozapine Complication That Kills More Patients Than Agranulocytosis
Every clozapine patient has a blood test schedule for a complication that is now rare and well controlled. Almost none has a bowel monitoring schedule for the one that is common, under-reported, and — when it progresses to ileus — carries a mortality that exceeds agranulocytosis. This chapter argues that the question "have your bowels been open?" belongs in every clozapine review, and shows what to do with the answer.
⏱ Bottom Line Up Front
- Clozapine slows the gut profoundly — colonic transit times run several-fold longer than normal. Objective transit studies find hypomotility in around 80% of patients, while only about a third report constipation when asked. The gap between those two figures is the whole chapter.
- Self-reported constipation has a sensitivity of roughly 18% for detecting objective hypomotility. Asking alone misses most cases — which is why prophylaxis, not symptom-triggered treatment, is the right default.
- Mortality from GI complications exceeds that from agranulocytosis. Among reported serious cases, case fatality runs from about 18% (Australia/New Zealand) to 33% (UK). In cohort data, ileus carried roughly 4.5-fold odds of death. Agranulocytosis sits at roughly 2–4%.
- Risk accumulates, but there is no safe early window. Cumulative ileus incidence approaches 5% at 20 years, and those who die have typically been on the drug longest — yet serious events cluster earlier than that implies, and hypomotility can progress to frank ileus within days.
- Prescribe prophylactic laxatives from the start — and screen for constipation before the first dose, as the label instructs. Ask about bowel function at every visit, with the same discipline applied to the blood counts.
- Minimize additive burden in two separate columns. Anticholinergics (benztropine, oxybutynin, antihistamines, tricyclics, paroxetine, olanzapine) and, listed separately because they are missed by anticholinergic searches, opioids.
- Dose matters for the endpoints that kill. Subjective constipation shows no consistent dose relationship — but objective colonic slowing tracks plasma level, and progression to ileus is dose-related.
📋 The Case
A 41-year-old man has been on clozapine for six years with excellent psychiatric stability. His ANC has been checked, without fail, more than a hundred times. He mentions at review that he "goes every few days, maybe less," and that his stomach has felt bloated. He isn't in pain. He's on clozapine, benztropine for tremor, and codeine for back pain. Two weeks later he presents with abdominal distension, vomiting, and no flatus for 48 hours; imaging shows a markedly dilated colon. He needed surgery. Every blood test was perfect. Nobody had ever asked about his bowels in a way that generated an action.
Note what he was taking. Benztropine is anticholinergic; codeine is an opioid. They slow the bowel by different mechanisms, and a clinician scanning for "anticholinergic burden" would have caught only one of them. Note also what he said — "every few days, maybe less" — the kind of answer that gets recorded and not acted on.
📊 The Scale of It
Two facts sit behind everything else in this chapter, and they pull in opposite directions: this is extremely common, and it is almost invisible to the way we usually look for it.
Both percentages are correct; they measure different things. The distance between the bars is the population you would otherwise never identify, and the amber box is the reason symptom screening cannot be the trigger for treatment.
Among reported serious cases, case fatality was approximately 18% in the Australia/New Zealand pharmacovigilance series (29 deaths among 160 serious cases) and approximately 33% in the UK series (172 deaths among 527). An earlier analysis of 102 life-threatening cases gave 7.3%. Reviews restricted to published case reports run higher still — around 44% — but that is the most selection-biased denominator of all.
None of these is the risk to an individual patient starting clozapine. They describe outcomes once a serious event has occurred. The cleanest population figure comes from 25-year cohort follow-up: ileus carried roughly 4.5-fold odds of death, and pneumonia roughly 2.8-fold. What all of it establishes is that this is a complication you cannot afford to let reach the serious stage.
It is tempting to summarise this as "a disease of the ten-year patient," and the mortality data invite it: in the UK series, those who died had been on clozapine a median of 11.3 years versus 4.8 years in survivors, with case fatality rising from about 3% in the first four years to about 25% at 10–14 years.
But the case series tell a different story about when events happen. Median time to ileus was around 4.2 years in the original series, and in the Australia/New Zealand pharmacovigilance data the median duration of treatment at the time of a serious event was only 2.5 years (mean dose 439 mg/day). Systematic review also notes hypomotility may progress to frank ileus rapidly — even within days.
So: risk accumulates, and the long-term patient is genuinely under-watched. But there is no safe early window, and a patient in year two is not exempt. Hold both numbers.
🔍 Recognize
Clozapine slows the gut through several mechanisms at once, and it is worth naming them separately because each suggests a different intervention.
The dashed arrow is the cruel part: the same receptor action that stalls the colon also dulls the sensation that would have prompted the patient to tell you. Naming 5-HT3 precisely also earns its keep later — if 5-HT3 antagonism is part of the problem, a selective 5-HT4 agonist is a mechanistically rational rescue.
The clinical spectrum runs from ordinary constipation through to a genuine surgical emergency. Unlike myocarditis, there is no protective window — risk persists for as long as the patient takes the drug.
Overflow diarrhoea belongs at the second box, not at the first. It is a presentation of impaction and is regularly mistaken for a resolving problem or a gastrointestinal infection — which is how a patient two boxes from the right ends up having their laxatives stopped.
The pain has a shape worth knowing. Early on it tends to be constant and localised above the obstructed segment. When it spreads and becomes diffuse, that shift raises the question of rupture and peritonitis. In a patient whose visceral sensation is already blunted, the shift may be the only clear signal you get.
What else to ask about and look for: reduced stool frequency, straining, hard stools, incomplete evacuation, abdominal bloating or distension, nausea and vomiting, absent flatus, and — deceptively — overflow diarrhea.
This is the crux of the chapter. Clozapine patients systematically under-report bowel symptoms, for reasons that compound each other: reduced visceral pain sensitivity means the warning sensation is blunted; sedation and negative symptoms reduce spontaneous reporting; cognitive impairment affects recall; and constipation feels too trivial or too embarrassing to raise in a psychiatric appointment. The FDA label makes the point explicitly: subjective symptoms may not reflect the true degree of hypomotility.
The size of that gap has been measured. When self-reported constipation was formally tested against objective transit studies in clozapine patients, it had a sensitivity of only about 18% (95% CI roughly 5–40%). Applying formal Rome criteria improved it to only about 50%.
This is the evidence base for the recommendation that follows. It is not that asking is worthless — it is that asking cannot be the trigger for treatment, because the trigger fires too rarely and too late. Prophylaxis for everyone; screening as surveillance rather than as a gate. And in a patient who cannot reliably report, a lower threshold for examination and imaging is warranted.
⚖️ Who Is at Higher Risk
| Factor | Detail |
|---|---|
| Anticholinergic co-prescription | Most modifiable. Antiparkinsonian anticholinergics for EPS (benztropine and relatives), sedating antihistamines including over-the-counter ones, tricyclics and paroxetine, oxybutynin, low-potency first-generation antipsychotics (chlorpromazine, thioridazine, flupenthixol), and olanzapine — which is anticholinergic in its own right and frequently combined with clozapine. Also count glycopyrrolate prescribed for sialorrhea (Chapter 16). In pharmacovigilance data, anticholinergic co-prescription showed a synergistic disproportionality signal for gastrointestinal stenosis and obstruction, not merely an additive one. |
| Opioids | Listed separately because they are not anticholinergic and are missed when clinicians scan for anticholinergic burden. Codeine for back pain is the classic. The label warns specifically about agents that decrease peristalsis. |
| Longer treatment duration | Risk accumulates rather than plateauing, and the patients who die have typically been on clozapine for a decade. The stable long-term patient is not the low-risk patient — but serious events also cluster in the first few years, so this is not permission to relax early. |
| Older age and female sex | Both identified in systematic review as risk factors for clozapine-induced ileus specifically. In the UK pharmacovigilance data those who died were older, at a median of 52 years. |
| Previous abdominal surgery | A history of gastrointestinal surgery — adhesions, resections — narrows the margin before hypomotility becomes obstruction. Several published re-initiation cases involved patients with prior bowel resections. |
| Sedentary lifestyle, low-fibre diet | Compounding rather than causal, and partly a consequence of sedation. Modifiable, and worth addressing — but not sufficient alone in significant hypomotility. |
| Beta-blockers (emerging signal only) | Pharmacovigilance analysis reported a synergistic signal for gastrointestinal stenosis and obstruction when beta-blockers are co-prescribed with clozapine, with a median time to onset around 395 days and about 14.5% of those cases fatal. This is a disproportionality signal, not causal evidence, and beta-blockers are commonly given for clozapine tachycardia — so confounding is plausible. Worth knowing; not yet a reason to withhold one. |
| Dose and plasma level — read this carefully | Three separate findings. Subjective constipation: no consistent relationship with dose or duration in meta-analysis. Objective colonic slowing: transit time did correlate with clozapine plasma level in the marker study, while showing no correlation with duration or total antipsychotic load. Progression to ileus: dose-related. So dose reduction is a reasonable lever against the serious endpoint and against measurable slowing — but should not be expected to relieve a patient's reported constipation, and is never a substitute for a laxative regimen. |
🛡 Prevent — From Day One (Actually, From Before Day One)
Given the prevalence and the poor sensitivity of symptom screening, prophylaxis rather than reaction is the right default. The label goes further than most clinicians realise: it instructs that constipation be screened for and treated before clozapine is initiated, not merely monitored afterwards.
| Move | Detail |
|---|---|
| Screen before initiation | Ask about baseline bowel function and treat existing constipation before the first dose. Document it — this is a labelled instruction, not best-practice garnish. |
| Prophylactic laxative at initiation | Start with the clozapine, not in response to symptoms. The only regimen studied specifically in this population is the Porirua Protocol — docusate with senna, augmented by macrogol (polyethylene glycol) where needed. In a small pre-and-post study (n = 14) it cut median colonic transit from about 110 to about 62 hours, and severe hypomotility from 64% to 21%. Notably, subjective constipation reports did not change significantly — further confirmation that symptoms are the wrong outcome measure. |
| Avoid bulk-forming agents | Relatively contraindicated in low-transit constipation. Psyllium, ispaghula and methylcellulose add volume without adding propulsion to an already stagnant colon and can worsen impaction. Dietary fibre eaten with adequate fluid is a different thing from a bulk-forming laxative — but if transit is already severely slowed, neither is the answer on its own. |
| Titrate slowly, avoid unnecessary dose | Slower titration and keeping the dose and plasma level no higher than the psychiatric response requires. This targets objective slowing and ileus risk, which is where the dose relationship actually lives. |
| Ask at every visit | Frequency, consistency, straining, bloating — documented. Treat it with the same routine as the blood count, while understanding you are performing surveillance with a blunt instrument, not ruling anything out. |
| Minimize anticholinergic burden | Review and remove where possible, and remember the list is longer than "benztropine": antihistamines, tricyclics, paroxetine, oxybutynin, low-potency first-generation antipsychotics, olanzapine, glycopyrrolate. |
| Review opioids separately | They will not appear on an anticholinergic burden scale. Look for them explicitly, and use a regimen appropriate to opioid-induced constipation if they cannot be stopped. |
| Check adherence to the laxative | A prescribed laxative that is not being taken is a common and invisible failure. Ask about it the way you would ask about the clozapine itself. |
| Educate explicitly | Tell the patient and any carer that bowel symptoms matter and what to report — this is a safety instruction, not general advice. |
The next chapter covers sialorrhea, where glycopyrrolate is widely used. It is an antimuscarinic, and systematic review specifically cautions against it in the context of clozapine-induced hypomotility. The two chapters pull in opposite directions in the same patient.
What sharpens the tension is that glycopyrrolate did not outperform placebo in the largest network meta-analysis of sialorrhea treatments. So the trade is not "effective drug versus GI risk" — it is a drug of unproven benefit that still lands on this chapter's ledger. That does not make it unusable, but it does mean a non-response should be recognised and the drug stopped, rather than left running indefinitely while the bowels quietly slow.
🔧 Manage Established Constipation
| Step | Detail |
|---|---|
| Escalate laxatives properly | An osmotic agent is the usual first move; combine with a stimulant and titrate to actual effect rather than leaving a token dose in place. Under-treatment is the norm. |
| Examine properly | Not "abdominal examination" as a box to tick: inspect for distension, palpate for tenderness and rebound, percuss, and auscultate for bowel sounds. Rectal examination where impaction is suspected — including, and especially, in overflow diarrhea. |
| Deprescribe contributors | Stop or substitute anticholinergics and opioids wherever possible. Count glycopyrrolate and olanzapine in this tally. |
| Image on suspicion | See the evaluation section below — imaging is what distinguishes bad constipation from ileus, and the threshold should be low. |
| Reconsider clozapine dose | A reasonable lever against progression to ileus and against objective slowing, though it should not be expected to relieve reported constipation. This rarely means stopping — clozapine is usually irreplaceable, and the aim is to make continued treatment safe. |
| Prucalopride | A selective 5-HT4 agonist promoting high-amplitude propagated colonic contractions, approved for chronic idiopathic constipation. Mechanistically well matched to clozapine's 5-HT3 blockade, with a solid evidence base in chronic constipation generally — but no published RCT in clozapine-treated patients. Guideline documents note a safety-database signal regarding suicidal ideation (a small number of events among several thousand subjects, causality unclear), which warrants explicit consideration in this population rather than dismissal. |
| Orlistat (minor option) | One randomised trial found orlistat reduced clozapine-induced constipation symptoms, presumably by loosening stool through reduced fat absorption — with the incidental attraction of also addressing clozapine-associated weight gain. A single trial; interesting rather than established. |
| Specialist input | Primary care or gastroenterology where constipation persists despite the above; surgical assessment is required for obstruction. |
🧪 Evaluate — When You Suspect It Has Progressed
Once the picture shifts from "constipated" to "possibly obstructed," the workup is a general medical and surgical one rather than a psychiatric one. It is worth knowing what will be requested, because in many services the psychiatrist is the one who has to start it.
| Investigation | What you are looking for |
|---|---|
| Full blood count | Leukocytosis suggesting ischaemia, perforation or sepsis — and, in this population, the ANC is being checked anyway. |
| Electrolytes and renal function | Dehydration and third-space losses; renal failure is a documented terminal complication. Electrolyte disturbance also worsens ileus in its own right. |
| Liver and pancreatic enzymes | To widen the differential for an acute abdomen rather than anchoring on the clozapine. |
| Abdominal X-ray, three positions | Supine, erect and lateral decubitus — dilated loops, air-fluid levels, and the distribution of gas. Fast, cheap, and usually the first useful image. |
| Chest X-ray | Two questions at once. Free air under the diaphragm indicates perforation. And in a clozapine patient, the same film answers the aspiration-pneumonia question raised in the next section. |
| Abdominal CT | The definitive study where obstruction, ischaemia or perforation is suspected, and where plain films are equivocal. |
🫁 The Upper-Gut Half — Why This Chapter Reaches the Chest
Clozapine-induced hypomotility is usually taught as a colonic problem. It isn't only colonic. Wireless motility capsule studies in clozapine-treated patients found delayed gastric emptying in around 41%, delayed small bowel transit in around 71%, and dysmotility spanning more than one region in around 59%. There is emerging evidence that oesophageal function is affected too, predisposing to aspiration of oropharyngeal contents.
That matters because pneumonia is one of the most consequential outcomes in long-term clozapine cohorts. In 25-year follow-up data, cumulative pneumonia incidence approached 30% at 20 years, with roughly 2.8-fold odds of death — and reduced CYP2C19 and CYP1A2 activity was associated with higher pneumonia risk, worth remembering in patients with unexpectedly high clozapine levels.
Three mechanisms converge in the same patient: sedation, sialorrhea producing a pool of oropharyngeal secretions (Chapter 16), and upper-gut hypomotility with delayed gastric emptying. None of the three is routinely assessed with aspiration as the endpoint in mind.
Practically: treat a chest infection in a clozapine patient as a possible aspiration event rather than a routine community-acquired pneumonia, review the sedation and the saliva alongside the bowels, and remember that infection also raises clozapine levels — so the pneumonia and the drug level are a two-way problem.
🚨 When It Becomes an Emergency
The transition from chronic constipation to a surgical emergency can be quiet, particularly in a patient with blunted pain perception. Four findings should generate same-day assessment and imaging rather than a follow-up appointment.
Absent flatus
The single best discriminator toward ileus or obstruction
Distension
Especially with several days without a bowel movement
Vomiting
Or pain that has spread from localised to diffuse
Overflow diarrhoea
This is impaction — examine, don't stop the laxatives
Add systemic signs — tachycardia, fever, hypotension — which may indicate ischemia or perforation. A clozapine patient presenting with an acute abdomen should be assumed to have clozapine-related hypomotility until proven otherwise, and the surgical team should be told about the drug explicitly, because it changes the index of suspicion. Given the case-fatality figures above, the cost of an unnecessary abdominal film is nowhere near the cost of a missed ileus.
🔁 If Clozapine Has Been Stopped — Re-initiation
Most of this chapter argues for keeping the drug and making it safe. But sometimes clozapine is stopped, either because the event was life-threatening or because someone else stopped it during the admission. What happens next matters, because the alternatives are usually worse for the illness — and because re-initiation in this context is genuinely done.
The evidence here is case reports, not trials. Read the outcomes as illustrations of what distinguishes a good attempt from a bad one rather than as a success rate.
| Reported outcome | What the case looked like |
|---|---|
| Succeeded | A woman on clozapine nine years, with prior large and small bowel resections, admitted with obstruction. A quetiapine trial was not clinically helpful. Clozapine was restarted at a low dose and she was discharged on 75 mg daily with good response. |
| Succeeded | A man who developed obstruction after his dose was increased from 450 to 600 mg, with a history of partial small bowel resection. Reducing back to 450 mg produced good improvement — the drug was never the wrong drug, the dose was. |
| Failed | A patient on 700 mg, also taking olanzapine and lithium, retitrated slowly to 350 mg with lactulose and docusate added. Constipation and faecal impaction recurred within three weeks. Note the anticholinergic burden that was never removed. |
| Failed | Clozapine-induced microscopic colitis. A switch to aripiprazole gave minimal improvement; reintroducing clozapine at just 25 mg daily brought the colitis back. Some phenotypes really are drug-specific. |
Start low and go slow — on the order of 25 mg/day to begin, with weekly increments no faster than about 100 mg. Treat the first four months as the high-risk period.
Monitor clozapine levels, not just the dose — this is the chapter where plasma level tracks objective slowing, so the number is doing real work. Monitor bowel activity on a defined schedule, folded into the metabolic monitoring visits so it actually happens. Start laxatives early rather than at the first symptom, for all the reasons in the screening section above. Attend to hydration, diet and activity alongside.
And clear the deck first. The failed case above was retitrated with olanzapine still on board. Removing anticholinergic and opioid burden is part of the re-initiation, not an afterthought to it.
If clozapine genuinely cannot be resumed, the agents with the least anticholinergic and hypomotility burden — aripiprazole and ziprasidone — are the usual destinations. Neither matches clozapine in treatment-resistant illness, which is precisely why re-initiation deserves a serious attempt first.
Clozapine Side Effects: Gastrointestinal
Discussion 4 of the Managing Clozapine Adverse Events lecture series. Presented by Dr. Harvinder Singh, MD. Series overview →
What the lecture covers
- Clozapine-induced gastrointestinal hypomotility and the receptor mechanisms behind it.
- Clinical signs — including how the abdominal pain evolves — and the full physical examination sequence.
- Risk factors, grouped around combination anticholinergic burden.
- Prevention, then management: laboratory and radiological evaluation when progression is suspected.
- Clozapine re-initiation, worked through four published cases — two that succeeded and two that failed.
Where the lecture and this chapter agree: the mechanism, the escalation to perforation and sepsis, the risk-factor set, the case for reducing polypharmacy and titrating slowly, and the position that life-threatening hypomotility means stopping the drug while milder disease means reducing the dose. Five things in this chapter came from the lecture and were absent from the earlier draft — the laboratory and imaging evaluation set, the four-part physical examination, the localised-to-diffuse pain evolution, previous abdominal surgery as a risk factor, and the entire re-initiation section.
Where the two diverge: the lecture's prevention slide advises adding laxatives at the early signs of constipation. This chapter argues for prophylaxis from initiation regardless of symptoms. That is not a disagreement about care so much as a change in the evidence: the diagnostic-accuracy study establishing that self-reported constipation has only about 18% sensitivity was published after the lecture was recorded. If asking detects roughly one case in five, symptoms cannot be the trigger. Where the two differ on this point, follow the chapter.
One nuance to hold alongside the lecture: its risk-factor slide lists high clozapine dose and levels, and the quiz answer confirms it. That is right for the endpoints that matter — objective colonic slowing correlates with plasma level, and ileus risk is dose-related. It is not true of the patient's reported constipation, which shows no consistent dose relationship. Both statements are correct about different things, which is why dose reduction is worth doing and still won't fix the symptom.
🪜 The Action Ladder
- Screen before the first doseAsk about baseline bowel function and treat existing constipation before initiating clozapine, as the label instructs. Record the answer.
- Start a laxative with the clozapineProphylaxis is the default, not the response — symptom-based screening is too insensitive to use as a trigger. Docusate plus senna, augmented with macrogol (the Porirua Protocol), is the only regimen studied in this population. Avoid bulk-forming agents.
- Ask specifically at every review — and check adherenceFrequency, consistency, bloating, and whether the laxative is actually being taken. Absence of complaint is not reassurance; it's a test with 18% sensitivity.
- Audit the constipating burden — in two columnsAnticholinergics in one (EPS agents, antihistamines, TCAs, paroxetine, oxybutynin, olanzapine, glycopyrrolate); opioids in the other. Different searches find them, and the anticholinergic signal appears synergistic rather than additive.
- Escalate rather than tolerateTitrate laxatives to actual effect; examine properly — inspect, palpate, percuss, auscultate; remember overflow diarrhea is impaction.
- Image when the story shiftsDistension, vomiting, absent flatus, or pain becoming diffuse → same-day bloods, three-position abdominal film, chest film for free air, CT where indicated, and surgical assessment.
- Adjust the dose, keep the drugDose and plasma-level reduction where feasible — against objective slowing and the ileus endpoint, not as a constipation treatment. Gastroenterology and prucalopride where refractory.
- If it was stopped, plan the return deliberatelyRe-initiate low and slow with level monitoring, treat the first four months as high risk, clear the anticholinergic burden first, and start laxatives from day one.
- Treat any chest infection as a possible aspiration eventReview sedation, sialorrhea, and gastric emptying together — and remember infection raises clozapine levels.
- This kills more clozapine patients than agranulocytosis. If that reorders one habit, make it asking about bowels at every visit.
- Asking has a sensitivity of about 18%. That one number justifies the entire prophylactic approach — you are not screening to decide whether to treat, you are treating everyone and screening to catch deterioration.
- Objective 80%, subjective 32%. Both figures are real; the difference between them is the population you would otherwise miss.
- Dose reduction and laxatives answer different questions. Reported constipation shows no consistent dose relationship — but objective transit tracks plasma level, and ileus risk is dose-related. Reduce the dose for the endpoint that kills, not for the symptom.
- Screen the bowels before the first dose, not just afterwards — that is what the label actually says, and almost nobody does it.
- Overflow diarrhea is impaction. Don't stop the laxatives; examine the patient.
- Opioids won't appear when you scan for anticholinergics. Codeine for back pain is the classic miss — and it was in this chapter's case.
- Olanzapine is on the anticholinergic list. Clozapine plus olanzapine is a common combination and a doubled burden that rarely gets counted as one.
- Pain that spreads is pain that has changed meaning. Localised above the blockage is bad; diffuse raises rupture and peritonitis.
- The stable ten-year patient is the high-risk patient — and year two is not safe either. Those who died had been on clozapine roughly twice as long as survivors, but serious events cluster earlier than that suggests and can progress within days.
- Absent flatus with distension is a surgical problem, not a constipation problem — image the same day, and get a chest film too.
- Tell the surgical team about the clozapine. It changes their index of suspicion in an acute abdomen.
- Pneumonia is part of this story. Delayed gastric emptying in roughly 40% and impaired oesophageal function put aspiration on the same mechanistic pathway.
- Stopping clozapine isn't necessarily the end of it. Re-initiation at low dose with slow titration and levels is documented to work — and the failures are instructive about why.
- No bowel movement for several days, especially with abdominal distension.
- Absent flatus — a key discriminator pointing toward ileus or obstruction.
- Vomiting, or abdominal pain that has spread from localised to diffuse.
- A tense, distended, or rebound-tender abdomen; absent bowel sounds.
- Overflow diarrhea in a patient with a history of constipation — assume impaction.
- Fever, tachycardia, or hypotension with abdominal signs — possible ischemia or perforation.
- Clozapine co-prescribed with an EPS anticholinergic, olanzapine, glycopyrrolate, or an opioid without a laxative in place.
- A long-term, well-controlled patient nobody has asked about bowels in years — the highest-risk group in the mortality data.
- Recurrent chest infection in a clozapine patient — consider aspiration and review sedation, sialorrhea, and gastric emptying together.
"I'm going to ask you about your bowels at every appointment, and I want you to know why — it isn't small talk. This medication slows the bowel down significantly, and because it can also dull the feeling in your abdomen, people often don't realize how blocked up they've become. We've found that asking about symptoms misses most of it, which is why I'll start you on a laxative from the beginning rather than waiting — that's standard, not a sign anything is wrong. Please tell me if you're going less often, if you feel bloated, or if you're straining, and do tell me if you stop taking the laxative. And treat these as urgent: not opening your bowels for several days with a swollen stomach, vomiting, or not passing any wind at all. Those need same-day assessment. One more thing — this stays relevant for as long as you're on the medication, not just at the start."
One clozapine effect left — the one patients actually complain about.
Constipation is the clozapine problem patients don't mention. Sialorrhea is the one they do — soaking pillows, embarrassment in public, and a genuine aspiration risk that connects it back to pneumonia. It's also pharmacologically counterintuitive: a drug with strong anticholinergic effects causing too much saliva. And its standard treatment is this chapter's risk factor. The last chapter of the clozapine set explains why, and what actually works.
Unlock the full course →References
- Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal "slow gut" reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699–709 — Australia/New Zealand case fatality among serious cases (29 of 160); median treatment duration 2.5 years at the time of a serious event.
- Every-Palmer S, Nowitz M, Stanley J, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross-sectional study. EBioMedicine. 2016;5:125–134 — radiopaque marker transit data; objective hypomotility in ~80%; colonic transit time correlated with clozapine plasma level (rho 0.451) but not with duration or total antipsychotic load.
- Every-Palmer S, Inns SJ, Ellis PM. Constipation screening in people taking clozapine: a diagnostic accuracy study. Schizophr Res. 2020 — self-reported constipation sensitivity ~18%; Rome criteria ~50%. The evidence base for universal prophylaxis.
- Every-Palmer S, Ellis PM, Nowitz M, et al. The Porirua Protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017 — docusate/senna with macrogol; transit ~110 → ~62 hours (n = 14).
- Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Cochrane Database Syst Rev. 2017.
- Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759–768 — 7.3% case fatality; median time to ileus 4.2 years.
- Handley SA, Every-Palmer S, Ismail A, Flanagan RJ. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992–2017. Br J Psychiatry. 2022 — 527 serious cases, 33% mortality; deaths at median 11.3 versus 4.8 years; fatality rising from ~3% (first 4 years) to ~25% (10–14 years).
- Gurrera RJ, Gearin PF, Love J, et al. Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. Acta Psychiatr Scand. 2022 — mechanism, risk factors including older age and female sex, bulk laxatives as relatively contraindicated, caution regarding glycopyrrolate, the orlistat trial, and the observation that hypomotility may progress to frank ileus within days.
- Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017 — pooled self-reported prevalence and comparison of case fatality with agranulocytosis.
- Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012.
- Partanen JJ, Häppölä P, Kämpe A, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry. 2024 — cumulative ileus incidence 5.3% at 20 years and pneumonia 29.5% at 20 years; ileus associated with roughly 4.5-fold odds of death and pneumonia 2.8-fold; CYP2C19 and CYP1A2 activity and pneumonia risk.
- Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019 — delayed gastric emptying ~41%, delayed small bowel transit ~71%, multi-regional dysmotility ~59%.
- Li D, Zhao Z, Chen Z, et al. Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. Naunyn Schmiedebergs Arch Pharmacol. 2025 — synergistic disproportionality signal with both anticholinergics and beta-blockers; median time to onset ~395 days; 14.5% of cases fatal. Hypothesis-generating only.
- Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592–598 — the combination anticholinergic burden framing, and the co-medication classes that contribute to it.
- Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association–American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023 — prucalopride efficacy and safety-database considerations.
- Fornaro M, et al. Network meta-analysis of pharmacological interventions for clozapine-induced sialorrhea, 2023 — cited here for the finding that glycopyrrolate did not outperform placebo, relevant to the cross-chapter anticholinergic ledger.
- McKinnon ND, Azad A, Waters BM, Livingston R. Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont). 2009;6(3):30–35 — successful low-dose re-initiation after obstruction in a patient with prior bowel resections.
- Rondla S, Crane S. A case of clozapine-induced paralytic ileus. Emerg Med J. 2007;24(2):e12 — obstruction following dose increase, resolving on dose reduction.
- Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry. 2008;16(3):216–219 — failed retitration with olanzapine and lithium co-prescribed.
- Pelizza L, De Luca P, La Pesa M, Borella D. Clozapine-induced microscopic colitis: a case report and review of the literature. J Clin Psychopharmacol. 2007;27(6):571–574 — recurrence on rechallenge at 25 mg daily.
- Çam B, Yavuz S, et al. Clozapine-induced ileus. Ther Adv Psychopharmacol. 2014;4(4):170–172 — the receptor pathway from M3 and H1 blockade through sedation and inactivity to hypomotility and its complications.
- Clozapine prescribing information — gastrointestinal hypomotility warning, the instruction to screen for and treat constipation prior to initiation, the statement that subjective symptoms may not reflect the degree of hypomotility, and the warning regarding co-prescribed anticholinergics and other agents that decrease peristalsis. Current labelling governs practice.
Responses